IntelGenx Technologies Corp.
General ticker "IGXT" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $29.7M (TTM average)
IntelGenx Technologies Corp. follows the US Stock Market performance with the rate: 0.1%.
Estimated limits based on current volatility of 0.0%: low 0.17$, high 0.17$
Factors to consider:
- US accounted for 18.6% of revenue in the fiscal year ended 2023-12-31
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.07$, 0.20$]
- 2024-12-30 to 2025-12-30 estimated range: [0.06$, 0.18$]
Financial Metrics affecting the IGXT estimates:
- Negative: Non-GAAP EPS, $ of -0.07 <= 0.04
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -147.87 <= 22.52
- Negative: Operating cash flow per share per price, % of -21.39 <= 1.79
- Positive: Industry inventory ratio change (median), % of -2.82 <= -0.28
- Negative: negative Operating income
- Positive: Interest expense per share, $ of 0.01 <= 0.10
- Negative: Industry operating cash flow per share per price (median), % of -13.30 <= 2.82
Short-term IGXT quotes
Long-term IGXT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.53MM | $0.95MM | $1.04MM |
| Operating Expenses | $9.52MM | $10.36MM | $10.53MM |
| Operating Income | $-7.98MM | $-9.41MM | $-9.49MM |
| Non-Operating Income | $-1.34MM | $-1.28MM | $-0.44MM |
| Interest Expense | $1.49MM | $1.28MM | $1.62MM |
| R&D Expense | $2.72MM | $3.03MM | $3.27MM |
| Income(Loss) | $-9.32MM | $-10.69MM | $-9.93MM |
| Taxes | $-0.01MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-9.31MM | $-11.97MM | $-9.93MM |
| Stockholders Equity | $3.87MM | $-3.42MM | $-12.25MM |
| Inventory | $0.06MM | $0.06MM | $0.07MM |
| Assets | $17.91MM | $9.19MM | $8.28MM |
| Operating Cash Flow | $-7.17MM | $-9.52MM | $-6.53MM |
| Capital expenditure | $0.11MM | $0.27MM | $0.18MM |
| Investing Cash Flow | $-5.07MM | $3.51MM | $1.17MM |
| Financing Cash Flow | $15.49MM | $2.96MM | $6.78MM |
| Earnings Per Share** | $-0.07 | $-0.07 | $-0.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.